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Many human skin diseases are caused by gene mutations 
that result in either the loss of protein or an altered protein 
function. To understand how these mutations cause disease 
and to find possible therapeutic targets, it is crucial to use 
not only cell culture approaches but also in vivo investi-
gations in a complex multicellular organism to assess 
the contributions of the macro- and microenvironment. 
Although clinical data provide a wealth of information on 
disease-causing mutations, it is often difficult to distinguish 
between cause and consequence in humans. The genetic 
and environmental variation is another complicating fac-
tor in understanding the underlying mechanisms that 
result in disease. Targeted genetic modifications in related 
mammals therefore offer great possibilities to investigate 
molecular mechanisms that underlie mammalian physi-
ology and disease. The mouse is one of the most relevant 
research organisms because it shares 99% genetic identi-
ty with humans, inbred strains exist, and it has been very 
well characterized on both the genetic and behavioral lev-
els (Paigen, 2003). Most importantly, the groundbreaking 
work of Mario Capecchi, Martin Evans, and Oliver Smithies 
in the 1980s, in which they discovered how to introduce 
specific gene modifications in mice using embryonic stem 
cells, opened the way to address directly the consequenc-
es of specific mutations. For this they received the Nobel 
Prize in Physiology or Medicine in 2007 (Vogel, 2007). We 
provide an overview of how to design (conditional) knock-
out mice and discuss their relevance for understanding 
human disease.
hOW TO creaTe a KnOcKOuT mOuse
A gene knockout is the manipulation of endogenous DNA 
that results in nonfunctionality or complete loss of the 
corresponding protein. The knockout of a gene offers the 
possibility to investigate its usual function by examining 
the consequences of loss of the encoding protein in a living 
organism. Capecchi, Evans, and Smithies established the 
gene knockout strategy by “gene targeting,” a method to 
introduce artificial DNA into mouse embryonic stem (ES) 
cells (Figure 1). ES cells are isolated from mouse blastocysts 
and they are pluripotent, which means they can differenti-
ate and give rise to any organ in the mouse. The method 
of gene targeting uses the natural process of homologous 
recombination in which two identical (homologous) parts 
of a DNA sequence are exchanged. The in vitro engineered 
BENEFITS OF CREATING KNOCKOUT MICE
•  A knockout is a mutation in a certain gene  
of interest resulting in the loss or decrease of 
function of the gene and the correlating gene 
product (protein).
•  In comparison to whole-body knockouts, 
conditional knockouts (using the Cre-loxP system) 
allow the deletion of a certain gene in one specific 
tissue of interest. 
•  Via gene targeting, an altered gene can be inserted  
in the genome of a mouse. 
LIMITATIONS 
•  Complete gene knockout does not always reflect 
the situation in human disease.
•  Redundancy of related gene products may 
compensate and thus not reveal gene function.
•  The in vivo situation in mice is not always fully 
representative of the in vivo situation in humans. 
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The discovery that this mechanism works in vitro as well 
as in other organisms, including mammals, has driven the 
generation of tissue-specific knockout constructs (Gu et 
al., 1994). Because the Cre-loxP system was developed 
first and is more widely used than the FLP-FRT system, the 
Cre-loxP technique will be discussed here. 
To create a tissue-specific conditional knockout mouse, 
two loxP sites, one upstream and one downstream of the 
functional part or the whole target gene to be inactivated, 
DNA (targeting construct) consequently contains sequenc-
es that are homologous to a part of the endogenous genom-
ic DNA that flank the target sequence.
After the targeting construct is delivered into the ES cell 
(mostly by electroporation), parts of the endogenous gene 
of interest are exchanged (recombined) with the modified 
engineered sequence (Figure 1). The targeting construct 
also contains an antibiotic resistance gene (in general, a 
“neo” gene that confers resistance to neomycin). Only ES 
cells that contain the recombined DNA will therefore sur-
vive the subsequent neomycin treatment. Because most 
DNA will integrate randomly into the genome, ES cell 
clones are then screened for homologous DNA recom-
bination. The “targeted” ES cells are then transferred to 
the blastocoel cavity of a mouse embryo, which then is 
implanted in the uterus of a surrogate mother. The recipi-
ent embryo in which the manipulated ES cells are injected 
already contains ES cells. The surrogate mother will give 
birth to chimeric mice, in which a proportion of the tis-
sues derive from the manipulated ES cell population, 
whereas the rest derive from the recipient embryo ES cells 
(so-called chimerism). If the manipulated ES cells contrib-
ute to the germline, further breeding of chimeric mice will 
result in homozygous gene-manipulated mice (Figure 1).
The creation of knockout mice has some drawbacks. 
First, the resistance gene that selects for positively targeted 
cells remains in the genome and may have an unpredict-
able effect on the mutant phenotype. Second, gene inacti-
vation will occur in every cell of the mouse, and its protein 
product will thus be absent during all important develop-
mental stages. Depending on the significance of the pro-
tein of interest in different developmental processes or cell 
lineages, this may compromise the viability of the knock-
out mouse. Finally, the protein’s absence prevents the 
investigator from discerning whether the observed effects 
are tissue autonomous or involve secondary effects of the 
surrounding tissue. Hence, the removal of the resistance 
cassette and a specific (conditional) knockout in either 
a certain tissue or a developmental stage might be ben-
eficial. For example, investigations on the protein Acvr1b 
were restricted because the total knockout led to embry-
onic lethality of affected mice. An epidermis-specific 
Acvr1b knockout was the solution to circumvent the early 
lethality and continue investigations on this protein in the 
epidermis (Qiu et al., 2011).
cOndiTiOnal Gene KnOcKOuT
Two analogous strategies were developed to overcome 
the above-mentioned limitations. Both involve site-specif-
ic recombination events discovered in bacteria or yeast, 
respectively (Lewandoski, 2001). In principle, an enzyme 
with a recombinase activity (Cre recombinase from bacte-
ria or FLP enzyme from yeast) recognizes short (25–50 bp), 
specific DNA sequences (loxP or FRT sites, respectively) 
and recombines the DNA region that is flanked by these 
sequences in a directed way. This means that, depend-
ing on the orientation of these small recognition sites, the 
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Figure 1. Generation of genetically modified mice. (a) Embryonic stem 
(ES) cells are isolated from blastocysts of pregnant mice. These cells are 
pluripotent; i.e., they can differentiate to every cell type of the adult 
organism. The ES cells are taken into cell culture and grown in nutrient 
medium. The modified DNA (see b) is then transfected into the cells by a 
process called electroporation. Not all of the cells will take up the DNA. 
Therefore, the cells are treated with an antibiotic, normally neomycin, 
and only cells containing the modified DNA and thus expressing the 
neomycin-resistant gene (neo) will survive. The modified ES cells are 
subsequently injected into a mouse blastocyst embryo, which is implanted 
into the uterus of a surrogate mother. The surrogate mother will give birth 
to so-called chimeric mice because their tissues are derived from both the 
modified ES cells and the recipient embryo's ES cells. Further breeding of 
the chimeric mice will lead to homozygous genetically modified mice. 
(b) After the targeting construct is transfected into the ES cell, homologous 
recombination will replace exon 1 with the neo gene, which results in a 
nonfunctional wild-type gene.
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must be introduced into the genome. This is achieved by gene 
targeting with an engineered DNA construct that contains 
loxP sites at the required positions (Figure 2). A mouse car-
rying a floxed gene (written geneflox/flox or genefl/fl) will not be 
a knockout mouse unless the Cre recombinase is expressed 
and recombines the flanked DNA region. The floxed mouse 
is then crossed with a second mouse that carries the Cre 
recombinase gene downstream of a tissue-specific promoter. 
Cre will be expressed in cells in which this promoter is 
active, recombine at the loxP sites, and accordingly delete 
the functional part or the whole gene of interest. This will 
result in a knockout not only in all cells in which Cre is 
active but, importantly, also in all descendants of these cells. 
Conversely, no recombination will occur and the expression 
of the gene of interest remains unaffected in tissues in which 
the promoter that drives Cre expression is not active.
Figure 2. schematic illustration of the cre-loxp system. To create a 
conditional knockout (KO) mouse, two independent mouse strains must 
be generated and crossed (Figure 1): a “Cre-mouse,” expressing the Cre 
recombinase under a chosen promoter that is specifically active in the 
tissue of interest, and a “floxed mouse.” In this example, exons 2 and 3 from 
the gene of interest are targeted and will be deleted. To this end, a target 
construct is introduced in embryonic stem cells, in which exons 2 and 3 
are flanked by loxP sites, that also includes a neomycin-resistance gene 
placed in the intron between exons 2 and 3. The construct also contains 
flanking regions that are homologous to regions of the gene of interest. 
Upon transfection, homologous recombination results in replacement of the 
endogenous gene of interest sequences with the target sequence, resulting 
in floxed exons 2 and 3 and hence a floxed “gene X” mouse. Crossing of the 
Cre mouse with the floxed mouse now gives rise to offspring in which the 
Cre gene is expressed in tissues where the chosen promoter is active. Only in 
these tissues does loxP site-specific recombination take place, resulting in the 
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For studies in dermatology the keratin 14 (K14) promoter 
is often used to drive an epidermis-specific Cre recombinase 
expression. The murine K14 is only expressed in the basal 
epidermal keratinocytes (in addition to the tongue, thymus 
epithelium, and certain cells in the eye; see Figure 3d). 
Importantly, K14 is expressed in oocytes and therefore must 
be carried only by males because in females expression 
would result in gene activation early during development. 
The mouse line with a K14-Cre;;genefl/fl genotype will there-
fore have a gene knockout in which the Cre recombinase 
is or was expressed, which is the whole skin epidermis, 
because all epidermal cells derive from the basal keratino-
cytes (Clayton et al., 2007; Qiu et al., 2011). Depending on 
the genotype of the parental mice, the knockout mice will 
come in a certain Mendelian ratio. Therefore, it is always 
mandatory to confirm the genotype via PCR and to check 
whether the gene and thus the protein really is ablated in the 
targeted tissue (Qiu et al., 2011). 
adVanTaGes and limiTaTiOns
The Cre-loxP system has been very useful to overcome 
embryonic and early postnatal lethality of classic gene 
knockout strategies. It also has the advantage of allowing 
investigations on the function of a gene/protein in a cell- 
or tissue-specific manner without indirect effects of the 
surrounding organs. Once a functional Cre line is generated 
it can be crossed to any floxed mouse strain and vice versa, 
entailing a very large variety of mouse models. There are also 
mouse lines available in which Cre recombinase expression 
is driven by a promoter that is already active in the germline, 
thus resulting in a total body knockout. International consor-
tia and companies nowadays offer the generation of knock-
out or floxed mice for almost every gene (Austin et al., 2004) 
and a large range of floxed and Cre mouse lines that have a 
reported biological relevance are available (e.g., http://infor-
matics.jax.org/recombinase.shtml). 
A potential technical limitation of mouse knockout tech-
nology could be that deletion of part of the gene does not 
result in a full loss of protein, as anticipated, but instead 
results in a truncated protein with different function. 
Furthermore, the introduction of a transgene (such as Cre) 
might affect more than just the target protein (Gangoda 
et al., 2012). Perhaps most importantly, the limitations of 
mouse knockouts to study human diseases mostly involve 
the disadvantages of the mouse model itself. Not every 
human disease will have a suitable mouse model and vice 
versa, and given the complexity of both organisms, a trans-
lation from the mouse model to humans will not always 
be directly possible (Seok et al., 2013). To simulate certain 
diseases, investigate gene functions, or test drug treatment 
in mice, it may also be inappropriate to knock out a gene. 
Instead, it might be suitable to use alternative strategies to 
influence the expression of the gene of interest, such as a 
gene knockdown to reduce but not completely prevent the 
gene expression (Wang et al., 2007). Further adjustments 
of the Cre-loxP system, for instance, to not delete but 
induce gene expression or introduce a point mutation into 
the gene of interest (so called knockins) or to control the 
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induction of Cre expression in a temporal manner (induc-
ible knockout/knockin), harbor diverse opportunities to 
investigate specific gene functions in vivo.
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To take the online quiz, follow the link below:  
http://www.classmarker.com/online-test/start/?quiz=rcf52728b592f502
1.  What determines where a conditional knockout 
occurs?
A.  The promoter that drives Cre expression.
B.  The promoter that drives neo expression.
C. The promoter that drives loxP expression.
2.  how is a modified dna construct introduced  
into the mouse genome?
A. Intradermal injection in adult mice.
B.  Via gene targeting and injection into ES cells.
C.  Application via drinking water in pregnant 
females.
3.  What is a conditional knockout?
A.  The deletion of a gene in every cell  
of the mouse.
B.  The knockout of a gene in only a certain tissue  
or at a certain developmental stage.
C. A knockout affecting more than one gene.
D.  A knockout inducible at a later time point.
4.  What is a floxed gene?
A.  The target sequence that shall be removed  
surrounded by two loxP sites.
B.  A mutated gene that is still producing a  
functional protein.
C.  A gene that has a high natural mutation rate.
5.  how can a conditional knockout mouse be created?
A.  By crossing a mouse carrying a floxed gene with 
a mouse expressing a Cre recombinase.
B.  By crossing mice carrying loxP sites  
with different orientations.
C.  By crossing a mouse carrying a gene for the Cre 
recombinase with one carrying the gene for FLP.
6.  What is a promoter?
A.  A gene that stimulates DNA replication  
in ES cells.
B.  A drug that enhances the embryonic growth  
rate in mice.
C.  A DNA fragment in front of a gene that  
drives its transcription.
QUESTIONS
This article has been approved for 1 hour of Category 1 CME credit.  
To take the quiz, with or without CME credit, follow the link under  
the “CME ACCREDITATION” heading.
Figure 3. Knockout and genotyping pcr. (a) Exons (E) 2 and 3 of the Acvr1b 
gene are flanked by loxP sites. Primers (P) 1–5 were designed for genotyping 
PCR. (b) Acvr1b genotyping using P1/P2 or P3/P4. The upper bands include a 
loxP site and are therefore bigger than the wild-type allele (lower bands). (c) 
PCR with primers P4/P5 detecting the recombined DNA and confirming that it is 
recombined only when Cre is expressed under the K14 promoter. (d) PCR with 
P4/P5 indicating in which tissue the recombination occurred (Qiu et al., 2011).
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SUPPLEMENTARY MATERIAL
A PowerPoint slide presentation appropriate for journal club or other 
teaching exercises is available at http://dx.doi.org/10.1038/jid.2013.457.
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